New Codes for Cytokine Release Syndrome (CRS)

October 1st, 2020 - Wyn Staheli, Director of Research
Categories:   Diagnosis Coding   Allergy|Immunology   Anesthesia|Pain Management   Cardiology|Vascular   Endocrinology   Home Health|Hospice   Neurology|Neurosurgery   Oncology|Hematology   Rheumatology  

Cytokine release syndrome (CRS), sometimes referred to as a cytokine storm, is a systemic inflammatory response triggered by a variety of reasons such as infections, certain drugs, or after treatment with some types of immunotherapy, (e.g., monoclonal antibodies and CAR-T cells).  It is characterized by a large, rapid release of cytokines into the blood. Cytokines are small proteins that help cells around the body communicate. When the immune system detects a threat, cells release cytokines to coordinate the body’s response. Too many cytokines cause harmful levels of inflammation throughout the body. Symptoms of CRS may include nausea, headache, tachycardia, hypotension, rash, shortness of breath, or in severe cases, death.

Chimeric Antigen Receptor T (CAR-T) Cell Therapy is an advancement in the treatment of relapsed or refractory leukemia and large b-cell lymphoma. In some instances complications of the therapy have been observed. Two of the most prevalent complications are Cytokine Release Syndrome (CRS) and Immune effector Cell Associated Neurotoxicity Syndrome (ICANS). 

In 2019, the American Society for Transplantation and Cellular Therapy (ASTCT) published a paper regarding the formal consensus for grading both CRS and ICANS. With this new consensus on grading, unique ICD-10-CM diagnosis codes were created to more effectively track the severity of patient symptoms in response to immune effector cell (IEC) therapy. 

The following table summarizes the new grading based on the consensus paper in the References. For additional information, see the consensus paper (see References below).

CRS Consensus Grading Table

CRS Parameter

Grade 1 (D89.831)

Grade 2 (D89.832)

Grade 3 (D89.833)

Grade 4 (D89.834)

Fever1

Temperature >38° C

Temperature >38° C

Temperature >38° C

Temperature >38° C

 

With

Hypotension

None

Not requiring vasopressors

Requiring a vasopressor with or without vasopressin

Requiring multiple vasopressors (excluding vasopressin)

 

And/or2

Hypoxia

None

Requiring low-flow nasal cannula3 or blow-by

Requiring high-flow nasal cannula3, facemask, nonrebreather mask, or Venturi mask

Requiring positive pressure (eg, CPAP, BiPAP, intubation and mechanical ventilation)

Notes:

  1. Fever is defined as temperature ≥38°C not attributable to any other cause. In patients who have CRS then receive antipyretic or anticytokine therapy such as tocilizumab or steroids, fever is no longer required to grade subsequent CRS severity. In this case, CRS grading is driven by hypotension and/or hypoxia.
  2. CRS grade is determined by the more severe event: hypotension or hypoxia not attributable to any other cause. For example, a patient with temperature of 39.5°C, hypotension requiring 1 vasopressor, and hypoxia requiring low-flow nasal cannula is classified as grade 3 CRS.
  3. Low-flow nasal cannula is defined as oxygen delivered at ≤6L/minute. Low flow also includes blow-by oxygen delivery, sometimes used in pediatrics.
  4. High-flow nasal cannula is defined as oxygen delivered at >6L/minute.
  5. Grade 5 (G89.8335) is defined as death due to CRS in which another cause is not the principle factor leading to this outcome.

It should be noted that, although ICD-10-CM codes were requested which further describe the grade levels for Immune effector cell-associated neurotoxicity syndrome (ICANS), at the time of publication there are no new codes for that syndrome. 

ICD-10-CM instructional notes specify that any underlying cause (e.g., complications following infusion and therapeutic injection [T80.89-], complications of transplanted organs and tissue [T86.-]) should be coded before using these new D89.83- codes. Associated manifestations should also be coded.

###

Questions, comments?

If you have questions or comments about this article please contact us.  Comments that provide additional related information may be added here by our Editors.


Latest articles:  (any category)

COVID Vaccine Coding Changes as of November 1, 2023
October 26th, 2023 - Wyn Staheli
COVID vaccine changes due to the end of the PHE as of November 1, 2023 are addressed in this article.
Medicare Guidance Changes for E/M Services
October 11th, 2023 - Wyn Staheli
2023 brought quite a few changes to Evaluation and management (E/M) services. The significant revisions as noted in the CPT codebook were welcome changes to bring other E/M services more in line with the changes that took place with Office or Other Outpatient Services a few years ago. As part of CMS’ Medicare Learning Network, the “Evaluation and Management Services Guide” publication was finally updated as of August 2023 to include the changes that took place in 2023. If you take a look at the new publication (see references below),....
Can We Score Interpretation of an EKG Towards E/M Medical Decision Making?
October 10th, 2023 - Aimee Wilcox
When EKGs are performed in the facility setting or even in the physician's office, what are the requirements for reporting the service and who gets credit for scoring data points for Evaluation and Management (E/M) medical decision making (MDM)? Let's take a look at a few coding scenarios related to EKG services to get a better understanding of why this can be problematic.
Accurately Reporting Signs and Symptoms with ICD-10-CM Codes
October 5th, 2023 - Aimee Wilcox
Coders often find themselves unsure of when to report a sign or symptom code documented in the medical record. Some coders find their organization has an EHR that requires a working diagnosis, which is usually a sign or symptom, be entered to order a test or diagnostic study or image. Understanding the guidelines surrounding when signs and symptoms should be reported is the first step in correct coding so let's take a look at some scenarios.
The 2024 ICD-10-CM Updates Include New Codes for Reporting Metabolic Disorders and Insulin Resistance
September 19th, 2023 - Aimee Wilcox
Diabetes is a chronic disease that just seems to consistently be increasing instead of improving resulting in a constant endeavor by medical researchers to identify causal effects and possible treatments. One underlying or precipitating condition that scientists have identified as a precipitating factor in the development of diabetes is insulin resistance, which is a known metabolic disorder. As data becomes available through claims reporting, additional code options become possible with ICD-10-CM.
Documenting and Reporting Postoperative Visits
September 12th, 2023 - Aimee Wilcox
Sometimes we receive questions regarding documentation requirements for specific codes or coding requirements and we respond with information and resources to support our answers. The following question was recently submitted: Are providers required to report postoperative services on claims using 99024, especially if there is no payment for that service? What documentation is required if you are reporting an unrelated Evaluation and Management (E/M) service by the same physician during the postoperative period? 
Understanding Gastroesophageal Reflux Disease and ICD-10-CM Coding
August 22nd, 2023 - Aimee Wilcox
Gastroesophageal reflux disease or GERD for short, is a disease that impacts millions of Americans on a weekly basis. Symptoms are uncomfortable, as are some of the tests used to diagnose it, but understanding the disease, tests, and treatments helps us better understand how to code the disease using ICD-10-CM codes.



Home About Terms Privacy

innoviHealth® - 62 E 300 North, Spanish Fork, UT 84660 - Phone 801-770-4203 (9-5 Mountain)

Copyright © 2000-2023 innoviHealth Systems®, Inc. - CPT® copyright American Medical Association